Metformina Eg

Metformin Hydrochloride, the active ingredient in Metformina Eg, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood‑sugar control. GNH USA supplies Metformina Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Eg is used within the antidiabetic drug class to manage disorders of glucose metabolism.

Type 2 diabetes mellitus: improves glycemic control and reduces HbA1c levels. Prediabetes (impaired fasting glucose): helps delay progression to overt diabetes when prescribed. Polycystic ovary syndrome (off‑label): may improve insulin resistance and menstrual regularity.

Metformina Eg may cause a range of adverse reactions. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea or upset stomach. - Diarrhea or loose stools. - Metallic taste in the mouth. - Abdominal discomfort or cramping. - Decreased appetite. - Unexplained weight loss.

Serious or Rare Side Effects: - Lactic acidosis (rare but life‑threatening). - Severe skin reactions such as Stevens‑Johnson syndrome. - Hepatic failure or significant liver enzyme elevation. - Hypoglycemia when combined with other glucose‑lowering agents. - Persistent vomiting leading to dehydration.

Before initiating Metformina Eg, clinicians should evaluate patient‑specific factors and monitor therapy. - Renal function assessment: avoid or adjust dose in severe renal impairment. - Hepatic status review: contraindicated in acute liver disease. - Monitor blood glucose regularly to detect hypoglycemia. - Use caution in elderly patients due to increased risk of lactic acidosis. - Limit alcohol consumption as it may potentiate metabolic acidosis. - Store at room temperature: keep in the original pack, protect from moisture.

Metformina Eg can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: heightened risk of hypoglycemia. - Diuretics (especially thiazides): may affect renal clearance. - ACE inhibitors or ARBs: monitor renal function and electrolytes.